Treatment of intrahepatic cholestatic diseases
Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
1. A method of treating primary biliary cholangitis by administering a therapeutically effective amount of a compound that is seladelpar or a salt thereof, where the amount of the compound is between 0.5 mg/day and 2 mg/day when the amount of the compound is calculated as seladelpar.
2. The method of claim 1 where the compound is administered orally.
3. The method of claim 1 where the amount of the compound is 0.5 mg/day, 1 mg/day, or 2 mg/day.
4. The method of claim 3 where the amount of the compound is 0.5 mg/day.
5. The method of claim 3 where the amount of the compound is 1 mg/day.
6. The method of claim 3 where the amount of the compound is 2 mg/day.
7. The method of claim 1 where the compound is administered once/day.
8. The method of claim 1 where the compound is administered between once/week and every other day.
9. The method of claim 1 where the compound is a seladelpar L-lysine salt.
10. The method of claim 9 where the compound is seladelpar L-lysine dihydrate salt.